Rebecca Kruse-Jarres
Hematology & Oncology · Seattle, WANPI 1720171937
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 48.9% of the total. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $1446.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$69K
- Genentech USA, Inc.$26K
- Hoffmann-la Roche Limited$9K
- CSL Behring$9K
- Pfizer$9K
- Genentech, Inc.$6K
- plus $12K from 11 others
Across 145 payments — averaging $25,336 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.3M
- Pfizer$199K
- CSL Behring$118K
- F. Hoffmann-la Roche AG$40K
- Shire North American Group Inc$7K
- Bayer$6K
What the payments were for
- Consulting fees$67,13948%
- Speaking & faculty fees$42,11530%
- Travel & lodging$22,81716%
- Food & beverage$6,2654%
- Education$1,9551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 35 | $68,626 |
| Genentech USA, Inc. | 28 | $25,917 |
| Hoffmann-la Roche Limited | 2 | $9,168 |
| CSL Behring | 5 | $9,133 |
| Pfizer | 3 | $8,875 |
| Genentech, Inc. | 4 | $6,381 |
| Regeneron | 1 | $3,745 |
| Shire North American Group Inc | 1 | $2,700 |
| Biomarin Pharmaceutical Inc. | 1 | $2,250 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $1,868 |
| Novo Nordisk AS | 1 | $983 |
| Novo Nordisk | 9 | $290 |
| Daiichi Sankyo Inc. | 1 | $150 |
| Grifols USA, LLC | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Spark Therapeutics, Inc. | 1 | $31 |
| HEMA Biologics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$91,937
- Idelvion$6,287
- HYMPAVZI$5,075
- HEMGENIX$2,845
- Non-Covered Product$1,868
- NovoSeven$983
- INJECTAFER$150
- Thrombate III$124
How this compares
$140,290 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclophosphamide | 21 | $1,863 |
| Celecoxib | 20 | $1,029 |
| Tranexamic Acid | 14 | $850 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $401 |
| Prednisone | 24 | $203 |
| Oxycodone Hcl | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.